Morepen Lab zooms on getting USFDA clearance for its bulk drug Montelukast Sodium

20 Dec 2017 Evaluate

Morepen Laboratories is currently trading at Rs. 27.80, up by 2.55 points or 10.10% from its previous closing of Rs. 25.25 on the BSE.

The scrip opened at Rs. 25.05 and has touched a high and low of Rs. 28.30 and Rs. 25.05 respectively. So far 1007401 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 28.85 on 05-Dec-2017 and a 52 week low of Rs. 14.80 on 11-Aug-2017.

Last one week high and low of the scrip stood at Rs. 28.30 and Rs. 23.60 respectively. The current market cap of the company is Rs. 1203.29 crore.

The promoters holding in the company stood at 34.54%, while Institutions and Non-Institutions held 18.80% and 46.66% respectively.

Morepen Laboratories has received approval from United States Food and Drug Administration (USFDA) for Montelukast Sodium, a bulk drug / API to sell in the US market. This gives Morepen an entry into the Rs 2000 crore US market for Montelukast. The first commercial orders for the bulk drug are expected in Q2 of FY 2018-19.

Morepen is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.

Morepen Laboratories Share Price

47.09 0.54 (1.16%)
08-May-2024 09:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.20
Dr. Reddys Lab 6019.00
Cipla 1383.50
Zydus Lifesciences 984.35
Lupin 1617.50
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.